替罗非班和瑞舒伐他汀对NSTE-ACS患者PCI术后肌酸激酶同工酶和肌钙蛋白及肾功能的影响  

The Effect of Tirofiban and Rosuvastatin Calcium for Patients with NSTE-ACS after PCI on Isoenzyme of Creatine Kinase and Troponin and Renal Function

作　　者：曹春辉[1] 黄军[2] 王仲华[1] 方永祥[1] 张晓红[1] 

机构地区：[1]郴州市第一人民医院心内科,湖南郴州423000 [2]郴州市第一人民医院肝胆外科,湖南郴州423000

出　　处：《中国医药指南》2012年第16期31-32,共2页Guide of China Medicine

摘　　要：目的探讨替罗非班和瑞舒伐他汀对非ST段抬高型急性冠状动脉综合征(non ST elevation acute coronary syndromes,NSTE-ACS)患者经皮冠状动脉介入(PCI)术后对肌酸激酶同工酶和肌钙蛋白及肾功能的影响。方法将62例NSTE-ACS患者随机分成强化组和对照组,强化组患者服用瑞舒伐他丁负荷剂量30mg/d,并先将盐酸替罗非班10μg/kg静脉推注,后按0.15μg/(kg min)速度静脉泵入,持续24～36h。对照组仅服用瑞舒伐他丁常规剂量10mg/d,预处理3～5d后行PCI术,术后观察两组的有效率情况,检测肌酸激酶同工酶(CK-MB)、肌钙蛋白(cTn1)和肌酐清除率(CrCI),进行分析比较。结果术后2周,强化组的总有效为90.32%,显著高于对照组的70.97%,P<0.05;术后24h,强化组的肌酸激酶同工酶(CK-MB)为(0.30±0.04)μg/L,肌钙蛋白(cTnI)为(0.25±0.1)μg/L,均显著低于对照组的(0.39±0.12)μg/L和(0.48±9.21)μg/L,肌酐清除率(CrCI)强化组为(54.92±6.35)mL/min,显著高于对照组(36.21±4.66)mL/min,P<0.05。结论对NSTE-ACS患者PCI术采用替罗非班和瑞舒伐他汀预处理减少了术后心肌损伤,增强了肾功能,且具有良好的临床疗效。Objective To investigate the effect of Tirofiban and Rosuvastatin Calcium on non-ST-segment elevation acute coronary syndrome （non ST elevation of acute coronary syndromes with NSTE-ACS） patients percutaneous coronary intervention （PCI） after surgery for isoenzyme of creatine kinase and troponin and renal function. Methods 62 patients with NSTE-ACS were randomly divided into the strengthening group and the control group. The strengthening group was taken with rosuvastatin small loading dose of 30rag / d, and took the first hydrochloric acid 10~tg/kg intravenous bolus of tirofiban, press 0.15 μg / （kg min） speed of intravenous infusion, last for 24-36 hours. The control group was only taken with Rosuvastatin Calcium with small conventional dose of 10rag / d, and took PCI 3-5 days after pretreatment. The efficient of the two groups after surgery was observed. Detect creatine kinase isoenzyme （CK-MB）, muscle calcium protein （cTnl -） and treat^nine clearance rate （CrCI）, and they were analyzed and compared. Results The total effective of the strengthening group 2 weeks after surgery was 90.32%, was significantly higher than the control group of 70.97%, P 〈0.05.24 hours after surgery, the rear^he kinase isoenzyme of the strengthening group was（CK-MB） （0.30~0.04） ktg / L, and troponin ! （cTnI） for （0.25~0.1）μg/L, were significantly lower than the control group （0.39-0.12） μg/L and （0.48-9.21） μg/L. The creatinine clearance rate （CrCI） of the strengthening group was （54.92~6.95） mL / rain, was significantly higher than the control group of （36.21~4.66） mL/min, P〈0.05. Conclusion Taking Tirofiban and Rosuvastatin Calcium for patients with NSTE-ACS after PCI can reduce postoperative myocardial injury, enhance renal function, and has a good clinical efficacy.

关 键 词：替罗非班 瑞舒伐他汀 NSTE-ACS PCI术 

分 类 号：R541.4[医药卫生—心血管疾病]